|
With its molecular chaperones, CytRx keeps an eye on the suspicious activities of proteins. The drug developer is working on small molecule therapies using its chaperone amplification technology, a method of boosting a certain corrective response in cells to protein misfires that cause disease. Its lead drug candidate is arimoclomol, a potential treatment for the neurodegenerative disorder Lou Gehrig's disease; it is also developing the compound as a treatment for stroke. Another candidate, iroxanadine, is undergoing clinical trials for the treatment of diabetic ulcers. In 2008 CytRx spun off its research programs related to RNA interference (RNAi) into publicly traded biotech firm RXi Pharmaceuticals.
|
| | | Contact Information | |
Address: |
11726 San Vicente Blvd., Ste. 650
Los Angeles, CA 90049
| | Phone: | 310-826-5648 | | Fax: | 310-826-6139 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 6.30 M | | Revenue Growth (1 yr): | (-16.00%) | | Employees (2008): | 35 | | Employee Growth (1 yr): | 29.60% |
|
|
Key People
| | • |
Chairman:
Max E. Link
| | • |
President, CEO, and Director:
Steven A. Kriegsman
| | • |
CFO:
John Y. Caloz
|
|
|
